Business Segment Information

12 Months Ended

Jul. 31, 2024

Business Segment Information [Abstract]

BUSINESS SEGMENT INFORMATION

NOTE 23 – BUSINESS SEGMENT INFORMATION

The Company conducts business as three operating segments, Healthcare, Infusion Technology and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s Chief Executive Officer who is the chief operating decision-maker. Following the Day Three Acquisition, the chief operating decision-maker began reviewing the operating results of Day Three and in accordance with the Company’s accounting policy, the Company concluded this resulted in a new operating segment, which the Company refers to as Infusion Technology.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Healthcare segment based primarily on research and development efforts and results of clinical trials and the Infusion Technology and Real Estate segments based primarily on results of operations.

The Healthcare segment is comprised of a majority equity interest in LipoMedix, Barer, Cornerstone and Rafael Medical Devices. To date, the Healthcare segment has not generated any revenues.

The Real Estate segment consists of the Company’s real estate holdings, which is currently comprised of a portion of a commercial building in Israel. The revenues, and (loss) income from operations of the 520 Property have been excluded from the Real Estate segment in the figures below due to its classification of held-for-sale and discontinued operations.

The Infusion Technology segment is comprised of a majority equity interest in Day Three. Revenues associated with the Infusion Technology segment include infusion technology revenue derived from Day Three’s Unlokt technology.

Operating results for the business segments of the Company are as follows:

(in thousands)	Healthcare			Infusion Technology			Real Estate		Total
Year Ended July 31, 2024
Revenues	$	—		$	355		$	282	$	637
(Loss) income from operations		(102,032	)		(675	)		80		(102,627	)

(in thousands)	Healthcare			Infusion Technology		Real Estate		Total
Year Ended July 31, 2023
Revenues	$	—		$	—	$	279	$	279
(Loss) income from operations		(15,121	)		—		78		(15,043	)

Total assets by segment are not provided to or reviewed by the CODM.

Geographic Information

Infusion Technology Segment

Revenue from the Infusion Technology segment is entirely from customers located in the United States.

Real Estate Segment

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-U.S. customers as a percentage of total revenues, which are inclusive of revenue from discontinued operations, were as follows (revenues by country are determined based on the location of the related facility):

Year Ended July 31,	2024			2023
Revenue from tenants located in Israel		100	%		53	%

Assets

Net property, plant, and equipment and total assets summarized by geographic area are as follows:

(in thousands)	United States		Israel		Total
July 31, 2024
Property, plant, and equipment, net	$	783	$	1,337	$	2,120
Total assets		93,434		3,398		96,832
July 31, 2023
Property, plant, and equipment, net	$	293	$	1,402	$	1,695
Total assets		95,244		3,585		98,829